Related references
Note: Only part of the references are listed.The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences
Yasset Perez-Riverol et al.
NUCLEIC ACIDS RESEARCH (2022)
The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors
Guangjian Yang et al.
FRONTIERS IN ONCOLOGY (2022)
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer
Le-Tian Huang et al.
LUNG CANCER (2022)
ColabFold: making protein folding accessible to all
Milot Mirdita et al.
NATURE METHODS (2022)
A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small-cell lung carcinoma
Ying Chen et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2022)
Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations
Miaomiao Li et al.
MOLECULES (2022)
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
Yurong Wang et al.
BMC CANCER (2021)
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)
Jennifer H. Foster et al.
CLINICAL CANCER RESEARCH (2021)
Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma
Seok-Young Kim et al.
CLINICAL CANCER RESEARCH (2021)
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Jacqulyne P. Robichaux et al.
NATURE (2021)
Highly accurate protein structure prediction for the human proteome
Kathryn Tunyasuvunakool et al.
NATURE (2021)
Structural basis of the effect of activating mutations on the EGF receptor
Ioannis Galdadas et al.
ELIFE (2021)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies
Xiang Zhai et al.
BIOCHEMISTRY (2020)
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal
Valerio Gristina et al.
CANCER TREATMENT REVIEWS (2020)
Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations
Haiyan Xu et al.
TARGETED ONCOLOGY (2020)
Structural Basis of AZD9291 Selectivity for EGFR T790M
Xiao-E Yan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase
Marc Hoemberger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non-Small Cell Lung Cancer and Response to EGFR TKIs
Chun-wei Xu et al.
TRANSLATIONAL ONCOLOGY (2020)
The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
Chao Zhao et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer*
Xingzhou Peng et al.
EUROPEAN JOURNAL OF CANCER (2020)
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
Anna Truini et al.
CLINICAL CANCER RESEARCH (2019)
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
Sheng-Kai Liang et al.
LUNG CANCER (2019)
Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments
Glenn R. Masson et al.
NATURE METHODS (2019)
Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation
Mahlet Z. Tamirat et al.
PLOS ONE (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Worldwide Frequency of Commonly Detected EGFR Mutations
Rondell P. Graham et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma
Giuseppina Improta et al.
MEDICAL ONCOLOGY (2018)
Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
Jing Huang et al.
THORACIC CANCER (2018)
Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma
Yingying Tian et al.
PLOS ONE (2018)
EGFR Mutation Subtypes Influence Survival Outcomes' following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients
Natalia Sutiman et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients
Jian Su et al.
ONCOTARGET (2017)
Deletion Mutations Keep Kinase Inhibitors in the Loop
Daniel M. Freed et al.
CANCER CELL (2016)
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Scott A. Foster et al.
CANCER CELL (2016)
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016
Daniel S. W. Tan et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Dynamics of the Tec-family tyrosine kinase SH3 domains
Justin M. Roberts et al.
PROTEIN SCIENCE (2016)
Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report
Yu-Ting Wang et al.
JOURNAL OF THORACIC DISEASE (2016)
Analytical Aspects of Hydrogen Exchange Mass Spectrometry
John R. Engen et al.
ANNUAL REVIEW OF ANALYTICAL CHEMISTRY, VOL 8 (2015)
ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
Scott C. Bresler et al.
CANCER CELL (2014)
Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance
Phillip A. Schwartz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Assessment of differences in the conformational flexibility of hepatitis B virus core-antigen and e-antigen by hydrogen deuterium exchange-mass spectrometry
Jessica Z. Bereszczak et al.
PROTEIN SCIENCE (2014)
The PDB_REDO server for macromolecular structure model optimization
Robbie P. Joosten et al.
IUCRJ (2014)
Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non-Small-Cell Lung Cancer
Victor H. F. Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
S. Yoshikawa et al.
ONCOGENE (2013)
Towards automated crystallographic structure refinement with phenix.refine
Pavel V. Afonine et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2012)
Probing protein interactions with hydrogen/deuterium exchange and mass spectrometry-A review
Andrew J. Percy et al.
ANALYTICA CHIMICA ACTA (2012)
Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
Jin H. Park et al.
BIOCHEMICAL JOURNAL (2012)
Clinical Outcomes in Non-Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR
Kuei-Pin Chung et al.
CLINICAL CANCER RESEARCH (2012)
Escherichia coli Processivity Clamp β from DNA Polymerase III Is Dynamic in Solution
Jing Fang et al.
BIOCHEMISTRY (2011)
Conformational Transitions in the Membrane Scaffold Protein of Phospholipid Bilayer Nanodiscs
Christopher R. Morgan et al.
MOLECULAR & CELLULAR PROTEOMICS (2011)
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
Scott C. Bresler et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
XDS
Wolfgang Kabsch
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer
Michael J. Eck et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
Recognition-domain focused chemosensors:: Versatile and efficient reporters of protein kinase activity
Elvedin Lukovic et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Phaser crystallographic software
Airlie J. McCoy et al.
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)
Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib
Roseann Mulloy et al.
CANCER RESEARCH (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib
Kendall D. Carey et al.
CANCER RESEARCH (2006)
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
David M. Jackman et al.
CLINICAL CANCER RESEARCH (2006)
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Xuewu Zhang et al.
CELL (2006)
Optimal Sox-based fluorescent chemosensor design for serine/threonine protein kinases
Melissa D. Shults et al.
ANALYTICAL BIOCHEMISTRY (2006)
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
GJ Riely et al.
CLINICAL CANCER RESEARCH (2006)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
Coot:: model-building tools for molecular graphics
P Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor
J Stamos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
